IGF-1 DES is a shortened version of IGF-1, the growth-factor signal involved in tissue growth and repair. Removing three amino acids from one end makes it bind much less to the body's carrier proteins, so more of it is briefly free to act. It is not an approved wellness or performance drug, and human dosing is not established.
IGF-1 DES is best framed as an experimental IGF-1R agonist analog with reduced IGF-binding-protein affinity and stronger apparent activity in some preclinical systems. Animal data show effects on nitrogen balance and muscle protein synthesis under catabolic conditions, but clinical translation is limited by absent human dosing, unknown PK, and serious IGF-axis class concerns around glucose regulation and growth signaling.
des(1-3)IGF-1 deletes the N-terminal Gly-Pro-Glu tripeptide from IGF-1, generating a 67-amino-acid ligand (~7,371 Da) that retains type-1 IGF-receptor activity while markedly reducing interaction with IGF-binding proteins. The translational hypothesis is that lower IGFBP sequestration increases receptor-level bioavailability (~10-fold higher apparent potency in vivo), amplifying PI3K/Akt/mTOR and MAPK signaling in tissue models. Unlike the engineered long-acting LR3, DES is a naturally-occurring, ultra-short-acting form.
IGF-1 DES sits in this atlas as a research analog of IGF-1 - mechanistically coherent and repeatedly studied in animal and cell models, but with no human therapeutic indication. Its signature is high local potency from escaping IGF-binding proteins, paired with an ultra-short half-life. The page keeps it distinct from native mecasermin and from the long-acting LR3 analog, and frames its dosing as a speculative research-math layer, not a protocol.
IGF-1 DES acts like a shortened version of IGF-1 that turns on growth and repair signals. Because it isn't held back by the body's binding proteins, more of it is briefly free to act right where it's applied.
DES's core pharmacology is IGF-1R agonism. Its defining property is reduced IGFBP sequestration, which raises free-ligand availability at tissue receptors and explains its higher apparent potency under IGFBP-rich conditions. The downstream biology (PI3K/Akt/mTOR, MAPK/ERK) is well established for the IGF axis; DES-specific human translation is not.
Mechanistically, loss of the N-terminal tripeptide (especially the residue-3 region) markedly reduces IGFBP binding while preserving IGF-1R engagement, increasing receptor-level bioavailability. This amplifies IRS-1/PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling. Native IGF-1 data are stronger than DES-specific data, and effects are model-dependent.
There is no validated or FDA-approved human dosing protocol for IGF-1 DES. This section exists only for calculator / data-model design and is labeled experimental - not medical advice, not for self-administration. Approved IGF-1 dosing information applies to mecasermin, not IGF-1 DES. Working unit: µg. The route models below are page-architecture placeholders, not clinical instructions.
| Band | Human protocol status | Example calculator targets | Basis |
|---|---|---|---|
| Low | Not established | 10-25 µg | Research-calculator placeholder only |
| Standard | Not established | 50-100 µg | Placeholder only |
| High | Not established | 150-200 µg | High-risk placeholder; not validated |
There is no validated human dose range. These are research-math example targets only - never "recommended dose" language.
| Body weight | 0.25 µg/kg | 0.5 µg/kg | 1.0 µg/kg |
|---|---|---|---|
| 55 kg | 13.75 µg | 27.5 µg | 55 µg |
| 65 kg | 16.25 µg | 32.5 µg | 65 µg |
| 75 kg | 18.75 µg | 37.5 µg | 75 µg |
| 85 kg | 21.25 µg | 42.5 µg | 85 µg |
| 95 kg | 23.75 µg | 47.5 µg | 95 µg |
| 105 kg | 26.25 µg | 52.5 µg | 105 µg |
Math-only interpolation; not validated for IGF-1 DES. Shown to illustrate arithmetic, not to imply a human-use protocol.
| Trigger | Page action | Rationale |
|---|---|---|
| Hypoglycemia symptoms or low glucose | HOLD / hard stop - clinician review | IGF-1 has insulin-like hypoglycemic effects per approved rhIGF-1 labeling |
| Active / suspected malignancy | HARD STOP | IGF axis is growth-signaling; mecasermin labeling warns/contraindicates neoplasia |
| New mass, unexplained growth, lymphoid swelling | HARD STOP / evaluate | Postmarketing neoplasia and tonsillar/adenoidal hypertrophy risks for rhIGF-1 |
| Severe headache, visual changes, nausea/vomiting | HOLD - eye exam | Intracranial hypertension reported with mecasermin |
| Edema, paresthesia, joint pain | De-escalate / hold | Mechanism-derived IGF-axis risk; not DES-validated |
| No response | Do not escalate automatically | No validated biomarker-response target exists for DES |
| Biomarker | Purpose | Validated for DES? |
|---|---|---|
| Fasting / fingerstick glucose | Hypoglycemia risk screen | No - extrapolated from rhIGF-1 |
| HbA1c | Metabolic context | No |
| Serum IGF-1 | Axis exposure context | No - DES assay cross-reactivity unclear |
| IGFBP-3 | IGF-axis context | No |
| CBC / CMP / lipids | General safety / metabolic baseline | No |
| Funduscopic exam | Intracranial-hypertension screen | No for DES; label concept for mecasermin |
| Cancer history / dermatologic exam | Growth-signal risk screen | No for DES; risk-based extrapolation |
| Joint / limp / hip-pain screen | Skeletal-growth concern | No for DES; extrapolated |
Research math only. Human IGF-1 DES dosing is not established; target values are illustrative examples, not recommendations. Formula: draw mL = target µg / concentration (µg/mL); U-100 units = draw mL x 100.
The numbers above are research arithmetic, not a dose recommendation. No validated human IGF-1 DES dose, route, or safety dataset exists; the FDA-approved IGF-1 product is mecasermin, a different molecule. The calculator is provided for reconstitution-math literacy and database modeling only - not for self-administration.
Verify against supplier COA and mass spec; the molecular formula is source-dependent and gray-market product quality is a recognized concern.
Reconstitute and store a labile ~7.4 kDa peptide with three disulfide bonds per product guidance; minimize freeze-thaw and avoid harsh agitation.
Keep DES distinct from native IGF-1 (mecasermin) and from LR3 in any database; they differ in PK, IGFBP binding, and regulatory status.
DES assay cross-reactivity with IGF-1 immunoassays may be unclear; interpret any IGF-1 measurement cautiously.
If IGF-axis exposure occurs in any setting, hypoglycemia is the most immediate analog risk; glucose is a risk-context marker, not a validated DES endpoint.
Any human-administration workflow is a hard stop - no validated protocol exists and the substance is WADA-prohibited.
IGF-1 DES's "combinations" are performance-circle theory, not validated protocols. Every pairing that adds IGF-axis or glucose-lowering activity compounds the same hazards - hypoglycemia, overgrowth, neoplasia concern - so the engine treats them as constraints, with malignancy risk as an absolute hard stop.
Active or suspected malignancy, a history of malignancy, an unexplained mass, or a high cancer-risk syndrome should be treated as a hard stop - approved rhIGF-1 labeling contains neoplasia warnings/contraindications and the IGF axis is growth-signaling, and DES escapes the IGFBP buffer that normally restrains it. Treat hypoglycemia-prone states, insulin use, pregnancy/lactation, open growth plates, and competitive-sport status as exclusion conditions. And keep IGF-1 DES distinct from native rhIGF-1 / mecasermin and from IGF-1 LR3 - they do not share PK, dosing, or safety claims.
Almost all human-relevant safety information for IGF-1 DES is inferred from the IGF-1 class - chiefly mecasermin's label - because no human DES safety dataset exists. Mecasermin's warnings (hypoglycemia, hypersensitivity, intracranial hypertension, lymphoid hypertrophy, slipped capital femoral epiphysis, scoliosis progression, neoplasia) frame the IGF axis as high-risk. DES adds the IGFBP-escape concern: by evading the binding proteins that normally restrain IGF-1, it presents a less-regulated growth signal, with no long-term human characterization.
| Condition | Concern | Severity |
|---|---|---|
| Active / suspected malignancy | Growth-factor signaling | High |
| History of malignancy | Recurrence / growth concern | High |
| Hypoglycemia or insulin use | Additive glucose-lowering risk | High |
| Diabetes on glucose-lowering meds | Unpredictable glucose effects | High |
| Pregnancy / lactation | No DES safety base | High |
| Pediatric / adolescent open growth plates | Growth-plate / skeletal risk | High |
| Intracranial-hypertension history | Class warning | High |
| Competitive athletics | Prohibited substance | High |
| Severe allergy to peptide / excipients | Hypersensitivity | High |
| Injection sterility uncertainty | Infection / endotoxin risk | High |
If IGF-axis exposure occurs in any context, hypoglycemia is the most immediate analog risk; glucose is a risk-context marker only, not a validated DES endpoint.
Cancer history/predisposition is a hard exclusion by analogy to mecasermin; DES's IGFBP escape makes the proliferative concern the dominant chronic risk.
Reflect the axis but are not validated to track DES, and assay cross-reactivity may be unclear; interpret only as research context.
COA + mass spec for identity, purity, and concentration; source-dependent formula and gray-market sourcing make this essential.
SCFE, scoliosis, and intracranial-hypertension cautions carry over from mecasermin's label as comparator-derived warnings.
Any human-administration workflow is a hard stop - no validated protocol, and the substance is WADA-prohibited.
IGF-1 DES has a coherent mechanistic rationale and repeated preclinical support for higher apparent potency versus full IGF-1 under IGFBP-influenced conditions. No human therapeutic trials of IGF-1 DES were identified - human evidence is absent for clinical efficacy, dosing, safety, and PK. The missing pieces are decisive: human PK, dose-response, route-specific safety, malignancy-risk characterization, and validated biomarkers.
A mechanistic review describing des(1-3)IGF-I as generally ~10-fold more potent than IGF-1 in hypertrophy/proliferation models, attributed to reduced IGFBP binding - the foundational characterization of the molecule's pharmacology.
In nitrogen-restricted rats, full-length IGF-1 and des(1-3)IGF-1 partly protected body-protein reserves and increased muscle protein synthesis - an in-vivo demonstration of the anabolic signal under catabolic stress.
In dexamethasone-treated catabolic rats, DES and LR3 variants were ~2.5-fold more potent than IGF-1, and in STZ-diabetic rats IGF variants restored growth 2.5-3x more potently than IGF-1, without correcting all insulin-dependent metabolism.
DES was used to distinguish IGFBP-mediated inhibition from receptor/signaling impairment in primate cartilage; aging reduced response to both IGF-1 and DES, and OA effects differed between the two.
In rat anterior-pituitary cells, des(1-3)IGF-1 more potently suppressed GH secretion than IGF-1, interpreted as reduced local IGFBP binding, and IGFBPs inhibited IGF-I/IGF-II activity but not des(1-3)IGF-I.
A native rhIGF-I study reported near-100% SC bioavailability and a ~6 h half-life in patients with GH-receptor deficiency. Included strictly as a comparator; IGF-1R structure/binding biology provides the mechanistic frame for both.
IGF-1 DES has a coherent mechanistic rationale and repeated preclinical support for higher apparent potency versus full IGF-1 under IGFBP-influenced conditions (~10-fold in some models, ~2.5-fold in catabolic rats). The missing pieces are decisive: human PK, dose-response, route-specific safety, clinical outcomes, malignancy-risk characterization, and validated biomarkers are all absent. It belongs on the Atlas as a research analog of IGF-1 - framed by mechanism, risk, regulatory status, and comparison to mecasermin and LR3 - not as a therapeutic protocol.
| Study | Model | Finding | Grade |
|---|---|---|---|
| Ballard review | Mechanistic | DES ~10x more potent than IGF-1 (reduced IGFBP binding) | P |
| Tomas 1991 | Nitrogen-restricted rats | Protected protein reserves; raised muscle protein synthesis | C |
| Tomas 1992 | Dexamethasone rats | DES/LR3 ~2.5x more potent than IGF-1 (catabolic) | C |
| Diabetic-rat model | STZ-diabetic rats | Variants restored growth 2.5-3x; metabolism not fully corrected | C |
| Loeser 2000 | Primate chondrocytes | Separated IGFBP inhibition from receptor/signaling in OA/aging | C |
| Simes 1991 | Rat pituitary cells | DES more potent than IGF-1 on GH secretion | P/C |
| Ross 1989 | Cell model | IGFBPs inhibited IGF-I/II but not des(1-3)IGF-I | P |
The key contrasts: DES and LR3 both escape IGF-binding proteins, but DES is the short-acting, high-local-potency truncation while LR3 is the long-acting, extended analog - close enough to compare, different enough to keep separate. Neither is mecasermin (the only approved native rhIGF-1), and MGF/PEG-MGF is a thinner IGF-1 splice-variant research class.
| Feature | IGF-1 DES | IGF-1 LR3 | Mecasermin / rhIGF-1 | MGF / PEG-MGF |
|---|---|---|---|---|
| Primary frame | Local / tissue IGF-1R signaling research | Long-acting IGF analog research | Severe primary IGFD growth failure | Muscle-repair hypothesis |
| Structure | Truncated (67 aa, minus Gly-Pro-Glu) | Extended (83 aa, Arg3 + N-term extension) | Native rhIGF-1 (70 aa) | IGF-1 splice variant |
| IGFBP binding | Low (escapes buffer) | Very low (escapes buffer) | Normal IGFBP-3/ALS binding | Distinct mechanism |
| Kinetic profile | Ultra-short / localized | Long-acting / systemic | ~6 h (native) | Variable (PEG extends) |
| Evidence tier | C/P (preclinical) | P/C (preclinical/culture) | A/B/D (FDA label) | P/D |
| Route context | Research models | Cell culture, animal | SC injection by Rx | Research / gray-market |
| Regulatory status | Not FDA-approved; WADA-prohibited | Not FDA-approved; WADA-prohibited | FDA-approved drug | Not FDA-approved |